These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 33051264

  • 1. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study.
    Urowitz MB, Ohsfeldt RL, Wielage RC, Dever JJ, Zakerifar M, Asukai Y, Ramachandran S, Joshi AV.
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33051264
    [Abstract] [Full Text] [Related]

  • 2. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.
    Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S.
    Ann Rheum Dis; 2019 Mar; 78(3):372-379. PubMed ID: 30610066
    [Abstract] [Full Text] [Related]

  • 3. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
    van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D.
    Rheumatology (Oxford); 2020 Feb 01; 59(2):281-291. PubMed ID: 31302695
    [Abstract] [Full Text] [Related]

  • 4. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
    Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, Wilson B, Molta C, Roth D, Gordon D.
    Lupus; 2016 Jun 01; 25(7):699-709. PubMed ID: 26936891
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 01; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 6. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A.
    Arthritis Rheumatol; 2020 Aug 01; 72(8):1314-1324. PubMed ID: 32275125
    [Abstract] [Full Text] [Related]

  • 7. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar 01; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 8. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, Ji B, Bass DL, Roth D.
    Arthritis Res Ther; 2020 May 04; 22(1):102. PubMed ID: 32366280
    [Abstract] [Full Text] [Related]

  • 9. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A.
    Arthritis Care Res (Hoboken); 2017 Jan 04; 69(1):115-123. PubMed ID: 27390293
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 04; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 11. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, BLISS-52 and -76 Study Groups.
    Ann Rheum Dis; 2014 May 04; 73(5):838-44. PubMed ID: 23524886
    [Abstract] [Full Text] [Related]

  • 12. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
    Lokhandwala T, Yue B, Coutinho AD, Bell CF.
    Lupus Sci Med; 2021 Feb 04; 8(1):. PubMed ID: 33558436
    [Abstract] [Full Text] [Related]

  • 13. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
    Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall'Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Quasny H, Roth DA, Stohl W, van Vollenhoven R, Wallace DJ, Petri M.
    Arthritis Care Res (Hoboken); 2022 Nov 04; 74(11):1822-1828. PubMed ID: 35439360
    [Abstract] [Full Text] [Related]

  • 14. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.
    Arthritis Rheumatol; 2018 Sep 04; 70(9):1450-1458. PubMed ID: 29648686
    [Abstract] [Full Text] [Related]

  • 15. Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
    van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, Tang Y, Thompson A.
    Arthritis Rheumatol; 2016 Sep 04; 68(9):2184-92. PubMed ID: 26992106
    [Abstract] [Full Text] [Related]

  • 16. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups.
    Lupus; 2013 Jan 04; 22(1):63-72. PubMed ID: 23263865
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
    Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S.
    Arthritis Care Res (Hoboken); 2019 Jun 04; 71(6):829-838. PubMed ID: 30320964
    [Abstract] [Full Text] [Related]

  • 18. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group.
    J Rheumatol; 2014 Feb 04; 41(2):300-9. PubMed ID: 24187095
    [Abstract] [Full Text] [Related]

  • 19. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
    Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I.
    Autoimmun Rev; 2017 Apr 04; 16(4):343-351. PubMed ID: 28216072
    [Abstract] [Full Text] [Related]

  • 20. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.